Orion Oyj/€ORNBV
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Orion Oyj
Orion Oyj is a Finnish pharmaceutical and diagnostics company engaged primarily in the research, development, manufacturing, and marketing of pharmaceuticals and active pharmaceutical ingredients. It operates through two main segments: the Pharmaceuticals segment, which includes proprietary drugs, specialty products, and animal health, and the Diagnostics segment, which comprises the Orion Diagnostica company focused on diagnostic tests. Founded in 1917, Orion is headquartered in Espoo, Finland, and operates globally with a significant presence in the Nordic countries and significant partnerships worldwide. Orion's strategic focus includes a strong emphasis on its proprietary drug portfolio, particularly in the central nervous system and oncology sectors, which constitutes a crucial component of its competitive strengths.
Ticker
€ORNBV
Sector
Primary listing
XHEL
Employees
3,700
Headquarters
Espo, Finland
Website
Orion Oyj Metrics
BasicAdvanced
€9.6B
25.37
€2.69
0.38
€1.64
2.40%
Price and volume
Market cap
€9.6B
Beta
0.38
52-week high
€71.60
52-week low
€40.78
Average daily volume
63K
Dividend rate
€1.64
Financial strength
Current ratio
1.863
Quick ratio
1.046
Long term debt to equity
14.789
Total debt to equity
34.569
Dividend payout ratio (TTM)
60.63%
Interest coverage (TTM)
54.15%
Profitability
EBITDA (TTM)
482.1
Gross margin (TTM)
61.84%
Net profit margin (TTM)
22.54%
Operating margin (TTM)
25.84%
Effective tax rate (TTM)
20.15%
Revenue per employee (TTM)
€450,000
Management effectiveness
Return on assets (TTM)
17.45%
Return on equity (TTM)
44.96%
Valuation
Price to earnings (TTM)
25.372
Price to revenue (TTM)
5.72
Price to book
10.45
Price to tangible book (TTM)
13.1
Price to free cash flow (TTM)
43.993
Free cash flow yield (TTM)
2.27%
Free cash flow per share (TTM)
1.551
Dividend yield (TTM)
2.40%
Growth
Revenue change (TTM)
33.19%
Earnings per share change (TTM)
63.01%
3-year revenue growth (CAGR)
16.09%
10-year revenue growth (CAGR)
5.22%
3-year earnings per share growth (CAGR)
23.29%
10-year earnings per share growth (CAGR)
5.88%
3-year dividend per share growth (CAGR)
3.02%
10-year dividend per share growth (CAGR)
2.35%
Bulls say / Bears say
Net sales in Q2 2025 rose 26.9% year-on-year to EUR 416.5 million and operating profit climbed 58.9% to EUR 104.6 million, prompting Orion to raise its full-year 2025 outlook to sales of EUR 1.63–1.73 billion and operating profit of EUR 400–500 million (Orion press release )
The EMA’s CHMP gave a positive opinion on June 20, 2025 for darolutamide (Nubeqa®) in metastatic hormone-sensitive prostate cancer and the FDA approved this same indication in June 2025, further expanding Orion’s leading prostate cancer portfolio (Orion press release )
Opening a new Biologics R&D Centre in Cambridge, UK in 2025 secures access to top biotech talent and strengthens the company’s efforts in large-molecule therapies, supporting Orion’s long-term pipeline growth (Orion press release )
The shutdown of the Protein and Antibody Engineering & Characterization unit in Turku, Finland may disrupt Orion’s biologics research and development productivity and cause delays to large-molecule projects as the group winds down operations in summer 2025 (Orion press release )
Research and development costs rose by 12.0% year-on-year to EUR 90.0 million in H1 2025, putting potential pressure on margins if new clinical programs fail to deliver returns in a timely manner (Orion press release )
Interest-bearing net liabilities increased by 20.8% to EUR 134.3 million as of June 30, 2025, raising the company’s financial leverage and possibly limiting flexibility for strategic investments (Orion press release )
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Orion Oyj stock?
Orion Oyj (ORNBV) has a market cap of €9.6B as of October 25, 2025.
What is the P/E ratio for Orion Oyj stock?
The price to earnings (P/E) ratio for Orion Oyj (ORNBV) stock is 25.37 as of October 25, 2025.
Does Orion Oyj stock pay dividends?
Yes, the Orion Oyj (ORNBV) stock pays dividends to shareholders. As of October 25, 2025, the dividend rate is €1.64 and the yield is 2.4%. Orion Oyj has a payout ratio of 60.63% on a trailing twelve-month basis.
When is the next Orion Oyj dividend payment date?
The next Orion Oyj (ORNBV) dividend payment date is unconfirmed.
What is the beta indicator for Orion Oyj?
Orion Oyj (ORNBV) has a beta rating of 0.38. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.